ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $6.95M; Long-term Debt, Excluding Current MaturitiesUSD $101.95M; Long-term DebtUSD $108.90M; Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $7.95M; Long-term Debt, Excluding Current MaturitiesUSD $101.47M; Long-term DebtUSD $109.42M; Long-Term Debt, Maturity, Year ThreeUSD $107.00M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $1.00M; Long-term Debt, Excluding Current MaturitiesUSD $107.96M; Long-term DebtUSD $108.96M; Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
ARCUTIS BIOTHERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.95M | $101.95M | $108.90M | (m) | $107.00M | (m) | $100.00M |
| 2026-03-31 | $7.95M | $101.47M | $109.42M | $107.00M | (m) | (m) | $100.00M |
| 2025-12-31 | $1.00M | $107.96M | $108.96M | (m) | (m) | (m) | $100.00M |
| 2025-12-31 | (m) | (m) | (m) | (m) | $107.00M | (m) | (m) |
| 2025-09-30 | $1.00M | $107.50M | $108.50M | (m) | $107.00M | (m) | $100.00M |
| 2025-06-30 | $1.00M | $107.05M | $108.05M | (m) | $107.00M | (m) | $100.00M |
| 2025-03-31 | (m) | $107.62M | $107.62M | (m) | $107.00M | (m) | $100.00M |
| 2024-12-31 | $0.00 | $107.20M | $107.20M | (m) | (m) | (m) | $100.00M |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $107.00M | (m) |
| 2024-09-30 | $99.51M | $105.09M | $204.61M | $213.90M | (m) | (m) | $200.00M |
| 2024-06-30 | (m) | $203.81M | $203.81M | $213.90M | (m) | (m) | $200.00M |
| 2024-03-31 | (m) | $202.80M | $202.80M | $213.90M | (m) | (m) | $200.00M |
| 2023-12-31 | (m) | $201.80M | $201.80M | (m) | (m) | (m) | $200.00M |
| 2023-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $213.90M | (m) | (m) |
| 2023-09-30 | (m) | $200.78M | $200.78M | (m) | (m) | $213.90M | $200.00M |
| 2023-06-30 | (m) | $199.77M | $199.77M | (m) | (m) | $213.90M | $200.00M |
| 2023-03-31 | (m) | $198.76M | $198.76M | (m) | (m) | $213.90M | $200.00M |
| 2022-12-31 | (m) | $197.77M | $197.77M | (m) | (m) | (m) | $200.00M |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $213.90M | (m) |
| 2022-09-30 | (m) | $196.75M | $196.75M | (m) | (m) | (m) | $200.00M |
| 2022-06-30 | (m) | $73.14M | $73.14M | (m) | (m) | (m) | $75.00M |
| 2022-03-31 | (m) | $72.74M | $72.74M | (m) | (m) | (m) | $75.00M |
| 2021-12-31 | (m) | $72.35M | $72.35M | (m) | (m) | (m) | $75.00M |
| 2020-12-31 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |